Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASH ...
Yahoo Finance

NASH/MASH Treatment Market to Surpass USD 31.76 Billion by 2033 as First-in-Class Drugs Redefine Fatty Liver Disease Management | According to DataM Intelligence

The approval of the first dedicated NASH treatment, Resmetirom (Rezdiffra) in 2024, marked a historic turning point for the industry. As the first therapy targeting MASH with histological improvement ...
The American Journal of Managed Care

MASH Care Demands More Than New Drugs: Meena Bansal, MD

Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes ...
Yahoo Finance

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
FierceBiotech

Chinese biotech's MASH candidate reduces liver fat in phase 2 trial

Chipscreen Biosciences' metabolic dysfunction-associated steatohepatitis (MASH) candidate reduced patients' liver fat levels, adding further momentum to drugs aimed at the condition. The Shenzhen, ...
FiercePharma

After monumental MASH nod, Madrigal plots $600M stock sale to support Rezdiffra launch

Just a few days ago, Madrigal Pharmaceuticals made history by winning FDA approval for its metabolic dysfunction-associated steatohepatitis (MASH) med Rezdiffra. Now that the launch is in sight, the ...
Business Insider

Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)

Patients with MASH/NASH treated with Rezdiffra experienced clinically meaningful and statistically significant improvements in emotional well-being and health distress Study results underscore the ...
Healio

MASH therapies still needed despite boom in GLP-1 use in liver disease

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. GLP-1 receptor agonist use in diabetes and obesity has ...
Nasdaq

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic ...

Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG) levels ...
MedPage Today

Clinical Challenges: Moving the Needle on Treatments for MASH

No FDA-approved therapy exists for metabolic dysfunction-associated steatohepatitis (MASH; formerly nonalcoholic steatohepatitis, or NASH), but the pipeline is full of potential candidates. "There's ...
Nasdaq

Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program

Week 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASH/MASH (F2-F3) to be Reported in March 2024 End-of-Phase 2 FDA Meeting Scheduled for the first quarter of 2024 to ...